Prestige BioPharma invests its expertise and resources in the development of biosimilars and new first-in-class antibody therapeutics.
PBP’s current biosimilar portfolio includes:

HD201 (Herceptin Biosimilar)

HD204 (Avastin Biosimilar)

PBP1502 (Humira Biosimilar)

PBP’s current first in class antibody therapeutics portfolio includes:

PBP1510 Anti-PAUF Antibody for Pancreatic Cancer

PBP1710 Anti-CTHRC1 Antibody for Solid Tumors

The first biosimilar of PBP, HD201 Trastuzumab, is in the midst of Phase III global trial, projecting market launch in 2019. HD204 Bevacizumab biosimilar follows closely, in the midst of Phase I and III trials from 2017 and market launch in 2020. PBP’s portfolio has been listed in the timeline below:

DrugCategoryIndication
HD201Biosimilar, Trastuzumab (Herceptin)Breast Cancer, Gastric Cancer
HD204Biosimilar, Bevacizumab (Avastin)Solid Tumors
PBP1502Biosimilar, Adalimumab (Humira)Arthritis
PBP1510First In Class AntibodyPancreatic Cancer
PBP1601Biosimilar, Denosumab Bone Loss, Osteoporosis
PBP1602Biosimilar, Aflibercept Macular Edema, Metastatic Colorectal Cancer, Retinopathy
PBP1603Biosimilar, Eculizumab Atypical Haemolytic Uremic Syndrome, Paraoxysmal Nocturnal Hemoglobinuria
PBP1701Biosimilar, Ipilimumab Metastatic Melanoma, Unresectable Melanoma
PBP1710First In Class AntibodySolid Tumors

Development Stage

  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3
  • HD201 TRASTUZUMAB BIOSIMILAR
    INDICATION: BREAST CANCER, GASTRIC CANCER
  • HD204 BEVACIZUMAB BIOSIMILAR
    INDICATION: SOLID TUMORS
  • PBP1502 ADALIMUMAB BIOSIMILAR
    INDICATION: ARTHRITIS
  • PBP1510 First-In-Class ANTIBODY
    INDICATION: PANCREATIC CANCER
  • PBP1601 DENOSUMAB BIOSIMILAR
    INDICATION: BONE LOSS OSTEOPOROSIS
  • PBP1602 AFLIBERCEPT BIOSIMILAR
    INDICATION: MACULAR EDEMA, METASTATIC COLORECTAL CANCER, RETINOPATHY
  • PBP1603 ECULIZUMAB BIOSIMILAR
    INDICATION: ATYPICAL HAEMOLYTIC UREMIC SYNDROME, PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
  • PBP1701 IPILIMUMAB BIOSIMILAR
    INDICATION: METASTATIC MELANOMA, UNRESECTABLE MELANOMA
  • PBP1710 First-In-Class ANTIBODY
    INDICATION: SOLID TUMORS
  • Discovery
  • Preclinical
  • Phase 1
  • Phase 2
  • Phase 3